Recent advances in the allosteric inhibition of glycogen phosphorylase

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 12, 2010, Pages 1139-1155

  Loughlin, W A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Allosteric inhibition; Glycogen phosphorylase; Inhibitor; Structure based drug design

Indexed keywords

GLUCOSE 1 PHOSPHATE; GLYCOGEN; GLYCOGEN PHOSPHORYLASE; INDOLE; PHOSPHATE BINDING PROTEIN;

ALLOSTERISM; ARTICLE; BINDING SITE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; LIGAND BINDING; NONHUMAN;

EID: 78549267168     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557511009011139     Document Type: Article

References (169)

1. Martin, W. H.; Hoover, D. J.; Armento, S. J.; Stock, I. A.; McPher-son, R. K.; Danley, D. E.; Stevenson, R. W.; Barrett, E. J.; Tread-way, J. L. Discovery of a human liver glycogen phosphorylase in-hibitor that lowers blood glucose in vivo. Proc. Natl. Acad. Sci.U.S.A., 1998, 95(4), 1776-1781.
2. Barford, D.; Johnson, L. N. The allosteric transition of glycogenphosphorylase. Nature (London, UK), 1989, 340, 609-616.
3. Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen phosphory-lase inhibitors for treatment of type 2 diabetes mellitus. Exp. Opin.Invest. Drugs, 2001, 10(3), 439-454.
4. Newgard, C. B., Littman D. R., van Genderen C., Smith, M., andFletterick R. J. Human brain glycogen phosphorylase. Cloning, se-quence analysis, chromosomal mapping, tissue expression, andcomparison with the human liver and muscle isozymes. J. Biol.Chem., 1988, 263(8), 3850-3957.
5. Johnson, L. N., Jenkins, J. A., Wilson, K. S., Stura, E. A., Zanotti,G. Proposals for the catalytic mechanism of glycogen phosphory-lase b prompted by crystallographic studies on glucose-1-phosphate. J. Mol. Biol., 1980, 140, 565-580.
6. Rath, V. L.; Ammirati, M.; Danley, D. E.; Ekstrom, J. L.; Gibbs, E.M.; Hynes, T. R.; Mathiowetz, A. M.; McPherson, R. K.; Olson, T.V.; Treadway, J. L.; Hoover, D. J. Human liver glycogen phos-phorylase inhibitors bind at a new allosteric site. Chem. Biol., 2000,7(9), 677-682.
7. Oikonomakos, N. G., Zographos, S. E., Skamnaki, V. T., Archon-tis, G. The 1.76 angstrom resolution crystal structure of glycogenphosphorylase B complexed with glucose, and CP320626, a poten-tial antidiabetic drug. Bioorg. Med. Chem., 2002, 10(5), 1313-1319.
8. Buchbinder, J. L., Fletterick, R. J., Role of the Active Site Gate ofGlycogen Phosphorylase in Allosteric Inhibition and SubstrateBinding. J. Biol. Chem., 1996, 271, 22305-22309.
9. Krasner, A. S. Use of glycogen phosphorylase inhibitors to inhibittumor growth. Eur. Pat. Appl.; EP 1177791 2002; 28.
10. Rousset, M.; Dussaulx, E.; Chevalier, G.; Zweibaum, A. Growth-related glycogen levels of human intestine carcinoma cell linesgrown in vitro and in vivo in nude mice. J. Nat. Cancer Inst., 1980,65, 885-889.
11. Oikonomakos, N. G. Glycogen phosphorylase as a molecular targetfor type 2 diabetes therapy. Curr. Protein Pept. Sci., 2002, 3(6),561-586.
12. Rosauer, K. G.; Ogawa, A. K.; Willoughby, C. A.; Ellsworth, K.P.; Geissler, W. M.; Myers, R. W.; Deng, Q.; Chapman, K. T.; Har-ris, G.; Moller, D. E. Novel 3,4-dihydroquinolin-2(1H)-one inhibi-tors of human glycogen phosphorylase a. Bioorg. Med. Chem. Lett.,2003, 13(24), 4385-4388.
13. Ekstrom, J. L.; Pauly, T. A.; Carty, M. D.; Soeller, W. C.; Culp, J.; Danley, D. E.; Hoover, D. J.; Treadway, J. L.; Gibbs, E. M.; Flet-terick, R. J.; Day, Y. S. N.; Myszka, D. G.; Rath, V. L. Structure-activity analysis of the purine binding site of human liver glycogenphosphorylase. Chem. Biol., 2002, 9(8), 915-924.
14. Somsak, L.; Nagy, V.; Hadady, Z.; Docsa, T.; Gergely, P. Glucoseanalog inhibitors of glycogen phosphorylases as potential antidia-betic agents: Recent developments. Curr. Pharm. Des., 2003,9(15), 1177-1189.
15. Lu, Z.; Bohn, J.; Bergeron, R.; Deng, Q.; Ellsworth Kenneth, P.; Geissler Wayne, M.; Harris, G.; McCann Peggy, E.; McKeever, B.; Myers Robert, W.; Saperstein, R.; Willoughby Christopher, A.; Yao, J.; Chapman, K. A new class of glycogen phosphorylase in-hibitors. Bioorg. Med. Chem. Lett., 2003, 13(22), 4125-4128.
16. Ogawa, A. K.; Willoughby, C. A.; Bergeron, R.; Ellsworth, K. P.; Geissler, W. M.; Myers, R. W.; Yao, J.; Harris, G.; Chapman, K. T. Glucose-lowering in a db/db mouse model by dihydropyridine dia-cid glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett.,2003, 13(20), 3405-3408.
17. Baker, D. J.; Timmons, J. A.; Greenhaff, P. L. Glycogen phos-phorylase inhibition in type 2 diabetes therapy: A systematicevaluation of metabolic and functional effects in rat skeletal mus-cle. Diabetes, 2005, 54(8), 2453-2459.
18. Baker, D. J.; Greenhaff, P. L.; MacInnes, A.; Timmons, J. A. Theexperimental type 2 diabetes therapy glycogen phosphorylase inhi-bition can impair aerobic muscle function during prolonged con-traction. Diabetes, 2006, 55(6), 1855-1861.
19. Buchbinder, J. L.; Guinovart, J. J.; Fletterick, R. J. Mutations inpaired -helixes at the subunit interface of glycogen phosphorylasealter homotropic and heterotropic cooperativity. Biochemistry,1995, 34(19), 6423-6432.
20. Fletterick, R. J.; Sprang, S. R. Glycogen phosphorylase structuresand function. Acc. Chem. Res., 1982, 15(11), 361-369.
21. Goldsmith, E. J.; Sprang, S. R.; Hamlin, R.; Xuong, N. H.; Flet-terick, R. J. Domain separation in the activation of glycogen phos-phorylase a. Science, 1989, 245, 528-532.
22. Fletterick, R. J.; Madsen, N. B. The structures and related functionsof phosphorylase a. Ann. Rev. Biochem., 1980, 49, 31-61.
23. Oikonomakos, N. G.; Skamnaki, V. T.; Tsitsanou, K. E.; Gavalas, N. G.; Johnson, L. N. A new allosteric site in glycogen phosphory-lase b as a target for drug interactions. Structure, 2000, 8(6), 575-584.
24. Barf, T. Intervention of hepatic glucose production. Small moleculeregulators of potential targets for type 2 diabetes therapy. Mini-Rev.Med. Chem., 2004, 4(8), 897-908.
25. Henke B. R.; Sparks S. M. Glycogen Phosphorylase Inhibitors. Mini-Rev. Med. Chem., 2006, 6(8), 845-857.
26. Baker, D. J.; Greenhaff, P. L.; Timmons, J. A. Glycogen phos-phorylase inhibition as a therapeutic target: a review of the recentpatent literature. Exp. Opin. Ther. Pat., 2006, 16(4), 459-466.
27. Somsak, L.; Czifrak, K.; Toth, M.; Bokor, E.; Chrysina, E. D.; Alexacou, K.-M.; Hayes, J. M.; Tiraidis, C.; Lazoura, E.; Leonidas, D. D.; Zographos, S. E.; Oikonomakos, N. G. New inhibitors ofglycogen phosphorylase as potential antidiabetic agents. Curr.Med. Chem., 2008, 15(28), 2933-2983.
28. Oikonomakos, N. G.; Somsak, L. Advances in glycogen phos-phorylase inhibitor design. Curr. Opin. Invest. Drugs, 2008, 9(4),379-395.
29. Sprang, S. R.; Goldsmith, E. J.; Fletterick, R. J.; Withers, S. G.; Madsen, N. B. Catalytic site of glycogen phosphorylase: Structureof the T state and specificity for -D-glucose. Biochemistry, 1982,21(21), 5364-5371.
30. Martin, J. L.; Veluraja, K.; Ross, K.; Johnson, L. N.; Fleet, G. W.J.; Ramsden, N. G.; Bruce, I.; Orchard, M. G.; Oikonomakos, N.G.; Papageorgiou, A. C.; Leonidas, D. D.; Tsitoura, H. S. Glucoseanalog inhibitors of glycogen phosphorylase: the design of poten-tial drugs for diabetes. Biochemistry, 1991, 30(42), 10101-10116.
31. Watson, K. A.; Chrysina, E. D.; Tsitsanou, K. E.; Zographos, S. E.; Archontis, G.; Fleet, G. W. J.; Oikonomakos, N. G. Kinetic andcrystallographic studies of glucopyranose spirohydantoin and glu-copyranosylamine analogs inhibitors of glycogen phosphorylase. Proteins: Struct. Funct. Bioinformatics, 2005, 61(4), 966-983.
32. Chrysina, E. D.; Kosmopoulou, M. N.; Tiraidis, C.; Kardakaris, R.; Bischler, N.; Leonidas, D. D.; Hadady, Z.; Somsak, L.; Docsa, T.; Gergely, P.; Oikonomakos, N. G. Kinetic and crystallographicstudies on 2-(-D-glucopyranosyl)-5-methyl-1,3,4-oxadiazole, -benzothiazole, and -benzimidazole, inhibitors of muscle glycogenphosphorylase b. Evidence for a new binding site. Protein Sci.,2005, 14(4), 873-888.
33. Anagnostou, E.; Kosmopoulou, M. N.; Chrysina, E. D.; Leonidas, D. D.; Hadjiloi, T.; Tiraidis, C.; Zographos, S. E.; Gyoergydeak, Z.; Somsak, L.; Docsa, T.; Gergely, P.; Kolisis, F. N.; Oikonoma-kos, N. G. Crystallographic studies on two bioisosteric analogues,N-acetyl-βD-glucopyranosylamine and N-trifluoroacetyl-βD-glucopyranosylamine, potent inhibitors of muscle glycogen phos-phorylase. Bioorg. Med. Chem., 2006, 14(1), 181-189.
34. Oikonomakos, N. G.; Kosmopoulou, M.; Zographos, S. E.; Leoni-das, D. D.; Chrysina, E. D.; Somsak, L.; Nagy, V.; Praly, J.-P.; Docsa, T.; Toth, B.; Gergely, P. Binding of N-acetyl-N'-βD-glucopyranosyl urea and N-benzoyl-N'-βD-glucopyranosyl urea toglycogen phosphorylase b. Kinetic and crystallographic studies. Eur. J. Biochem., 2002, 269(6), 1684-1696.
35. Oikonomakos, N. G.; Zographos, S. E.; Skamnaki, V. T.; Archon-tis, G. The 1.76.ANG. resolution crystal structure of glycogenphosphorylase b complexed with glucose, and CP 320626, a poten-tial antidiabetic drug. Bioorg. Med. Chem., 2002, 10(5), 1313-1319.
36. Chrysina, E. D.; Oikonomakos, N. G.; Zographos, S. E.; Kos-mopoulou, M. N.; Bischler, N.; Leonidas, D. D.; Kovacs, L.; Docsa, T.; Gergely, P.; Somsak, L. Crystallographic studies on -and -D-glucopyranosyl formamide analogues, inhibitors of glyco-gen phosphorylase. Biocatal. Biotrans., 2003, 21, 233-242.
37. Martin, J. L.; Johnson, L. N.; Withers, S. G. Comparison of thebinding of glucose and glucose 1-phosphate derivatives to T-stateglycogen phosphorylase b. Biochemistry, 1990, 29(44), 10745-10757.
38. Khan, M. T. H. Sugar-derived heterocycles and their precursors asinhibitors against glycogen phosphorylases (GP). Top. Heterocycl.Chem., 2007, 9, 33-52.
39. Felfoldi, N.; Toth, M.; Chrysina, E. D.; Charavgi, M-D.; Alexacou, K-M.; Somsak, L. Synthesis of new glycosyl biuret and urea de-rivatives as potential glycoenzyme inhibitors. Carbohydr. Res.,2010, 345(2), 208-213.
40. Czako, Z.; Juhasz, L.; Kenez, A.; Czifrak, K.; Somsak, L.; Docsa, T.; Gergely, P.; Antus, S. Synthesis and glycogen phosphorylaseinhibitory activity of N-(-D-glucopyranosyl)amides possessing1,4-benzodioxane moiety. Bioorg. Med. Chem., 2009, 17(18),6738-6741.
41. Jeon, C. Y.; Murray, M. B. Diabetes mellitus increases the risk ofactive tuberculosis: a systematic review of 13 observational studies PLoS Med., 2008, 5(7), 1091-1101.
42. Bisht, S. S.; Fatima, S.; Tamrakar, A. K.; Rahuja, N.; Jaiswal, N.; Srivastava, Ar. K.; Tripathi, R. P. Synthetic studies in butenonyl C-glycosides: Preparation of polyfunctional alkanonyl glycosides andtheir enzyme inhibitory activity. Bioorg. Med. Chem. Lett., 2009,19(10), 2699-2703.
43. Patani, G. A.; LaVoie, E. J. Bioisosterism: A rational approach indrug design. Chem. Rev., 1996, 96(8), 3147-3176.
44. Lima, L. M. A.; Barreiro, E. J. Bioisosterism: a useful strategy formolecular modification and drug design. Curr. Med. Chem., 2005,12(1), 23-49.
45. Wagener, M.; Lommerse, J. P. M. The quest for bioisosteric re-placements. J. Chem. Inf. Model., 2006, 46(2), 677-85.
46. Chrysina, E. D.; Bokor, E.; Alexacou, K-M.; Charavgi, M-D.; Oikonomakos, G. N.; Zographos, S. E.; Leonidas, D. D.; Oikono-makos, N. G.; Somsak, L. Amide-1,2,3-triazole bioisosterism: theglycogen phosphorylase case. Tetrahedron Asymmetry, 2009, 20(6-8), 733-740.
47. Alexacou, K-M.; Hayes, J. M.; Tiraidis, C.; Zographos, S. E.; Leonidas, D. D.; Chrysina, E. D.; Archontis, G.; Oikonomakos, N.G.; Paul, J. V.; Varghese, B.; Loganathan, D. Crystallographic andcomputational studies on 4-phenyl-N-(-D-glucopyranosyl)-1H-1,2,3-triazole-1-acetamide, an inhibitor of glycogen phosphory-lase: comparison with -βD-glucose, N-acetyl-βD-glucopyranosylamine and N-benzoyl-N'-βD-glucopyranosyl ureabinding. Proteins: Struct. Funct. Bioinformatics, 2008, 71(3),1307-1323.
48. Bokor, E.; Docsa, T.; Gergely, P.; Somsak, L. Synthesis of 1-(glucopyranosyl)-1,2,3-triazoles and their evaluation as glycogenphosphorylase inhibitors. Bioorg. Med. Chem., 2010, 18(3), 1171-1180.
49. Cheng, K.; Liu, J.; Liu, X.; Li, H.; Sun, H.; Xie, J. Synthesis ofglucoconjugates of oleanolic acid as inhibitors of glycogen phos-phorylase. Carbohydr. Res., 2009, 344(7), 841-850.
50. Toth, M.; Kun, S.; Bokor, E.; Benltifa, M.; Tallec, G.; Vidal, S.; Docsa, T.; Gergely, P.; Somsak, L.; Praly, J-P. Synthesis and struc-ture-activity relationships of C-glycosylated oxadiazoles as inhibi-tors of glycogen phosphorylase. Bioorg. Med. Chem., 2009, 17(13),4773-4785.
51. Benltifa, M.; Hayes, J. M.; Vidal, S.; Gueyrard, D.; Goekjian, P.G.; Praly, J-P.; Kizilis, G.; Tiraidis, C.; Alexacou, K-M.; Chrysina, E. D.; Zographos, S. E.; Leonidas, D. D.; Archontis, G.; Oikono-makos, N. G. Glucose-based spiro-isoxazolines: A new family ofpotent glycogen phosphorylase inhibitors. Bioorg. Med. Chem.,2009, 17(20), 7368-7380.
52. Nagy, V.; Benltifa, M.; Vidal, S.; Berzsenyi, E.; Teilhet, C.; Czi-frak, K.; Batta, G.; Docsa, T.; Gergely, P.; Somsak, L.; Praly, J-P. Glucose-based spiro-heterocycles as potent inhibitors of glycogenphosphorylase. Bioorg. Med. Chem., 2009, 17(15), 5696-5707.
53. Cecioni, S.; Argintaru, O-A.; Docsa, T.; Gergely, P.; Praly, J-P.; Vidal, S. Probing multivalency for the inhibition of an enzyme:glycogen phosphorylase as a case study. New J. Chem., 2009,33(1), 148-156.
54. Soman, G.; Philip, G. Nature of the binding site for aromatic com-pounds in glycogen phosphorylase b. Biochem. J., 1975, 147, 369-371.
55. Kasvinsky, P. J.; Shechosky, S.; Fletterick, R. J. Synergistic regula-tion of phosphorylase a by glucose and caffeine. J. Biol. Chem.,1978, 253(24), 9102-9106.
56. Sprang, S.; Fletterick, R.; Stern, M.; Yang, D.; Madsen, N.; Stur-tevant J. Analysis of an allosteric binding site: the nucleoside in-hibitor site of phosphorylase a. Biochemistry, 1982, 21(9), 2036-2048.
57. Tsitsanou, K. E.; Skamnaki, V. T.; Oikonomakos, N. G. StructuralBasis of the Synergistic Inhibition of Glycogen Phosphorylase a byCaffeine and a Potential Antidiabetic Drug. Arch. Biochem. Bio-phys., 2000, 384(2), 245-254.
58. Oikonomakos, N. G.; Schnier, J. B.; Zographos, S. E.; Skamnaki, V. T.; Tsitsanou, K. E.; Johnson, L. N. Flavopiridol inhibits glyco-gen phosphorylase by binding at the inhibitor site. J. Biol. Chem.,2000, 275, 34566-34573.
59. Kosmopoulou, M. N.; Leonidas, D. D.; Chrysina, E. D.; Eisen-brand, G.; Oikonomakos, N. G. Indirubin-3'-aminooxy-acetate in-hibits glycogen phosphorylase by binding at the inhibitor and theallosteric site. Broad specificities of the two sites. Lett. Drug Des.Discov., 2005, 2(5), 377-390.
60. Kosmopoulou M. N; Leonidas D. D; Chrysina E. D; Bischler N.; Eisenbrand G.; Sakarellos C. E; Pauptit R.; Oikonomakos N. G. Binding of the potential antitumour agent indirubin-5-sulphonateat the inhibitor site of rabbit muscle glycogen phosphorylase b.Comparison with ligand binding to pCDK2-cyclin A complex. Eur.J. Biochem., 2004, 271(11), 2280-90.
61. Hampson, L. J.; Arden, C.; Agius, L.; Ganotidis, M.; Kosmopou-lou, M. N.; Tiraidis, C.; Elemes, Y.; Sakarellos, C.; Leonidas, D.D.; Oikonomakos, N. G. Bioactivity of glycogen phosphorylase in-hibitors that bind to the purine nucleoside site. Bioorg. Med.Chem., 2006, 14(23), 7835-7845.
62. Deng, Q.; Lu, Z.; Bohn, J.; Ellsworth, K. P.; Myers, R. W.; Geissler, W. M.; Harris, G.; Willoughby, C. A.; Chapman, K.; McKeever, B.; Mosley, R. Modeling aided design of potent glyco-gen phosphorylase inhibitors. J. Mol. Graph. Model., 2005, 23(5),457-464.
63. Oikonomakos, N. G.; Tsitsanou, K. E.; Zographos, S. E.; Skam-naki, V. T.; Goldmann, S.; Bischoff, H. Allosteric inhibition ofglycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyri-dine-3,5,6-tricarboxylate. Protein Sci., 1999, 8(10), 1930-1945.
64. Wang, J. H.; Tu, J. I.; Lo, F. M. Effect of glucose 6-phosphate onthe nucleotide site of glycogen phosphorylase b. General approachfor negative heterotropic interactions. J. Biol. Chem., 1970, 245,3115-3121.
65. Melpidou, A. E.; Oikonomakos, N. G. Effect of glucose-6-P on thecatalytic and structural properties of glycogen phosphorylase a. FEBS Lett., 1983, 154(1), 105-110.
66. Johnson, L. N.; Snape, P.; Martin, J. L.; Acharya, K. R.; Barford, D.; Oikonomakos, N.G. Crystallographic binding studies on the al-losteric inhibitor glucose-6-phosphate to T state glycogen phos-phorylase b. J. Mol. Biol., 1993, 232(1), 253-67.
67. Kristiansen, M.; Andersen, B.; Iversen, L. F.; Westergaard, N.Identification, synthesis, and characterization of new glycogenphosphorylase inhibitors binding to the allosteric AMP site. J. Med.Chem., 2004, 47(14), 3537-3545.
68. Burley, S. K.; Petsko, G. A. Weakly polar interactions in proteins. Adv. Protein Chem., 1988, 39, 125-89.
69. Zographos, S. E.; Oikonomakos, N. G.; Tsitsanou, K. E.; Leonidas, D. D.; Chrysina, E. D.; Skamnaki, V. T.; Bischoff, H.; Goldmann, S.; Watson, K. A.; Johnson, L. N. The structure of glycogen phos-phorylase b with an alkyl-dihydropyridine-dicarboxylic acid com-pound, a novel and potent inhibitor. Structure, 1997, 5(11), 1413-1425.
70. Klabunde, T.; Wendt, K. U.; Kadereit, D.; Brachvogel, V.; Burger, H.-J.; Herling, A. W.; Oikonomakos, N. G.; Kosmopoulou, M. N.; Schmoll, D.; Sarubbi, E.; Von Roedern, E.; Schoenafinger, K.; De-fossa, E. Acyl Ureas as Human Liver Glycogen Phosphorylase In-hibitors for the Treatment of Type 2 Diabetes. J. Med. Chem.,2005, 48(20), 6178-6193.
71. Oikonomakos, N. G.; Kosmopoulou, M. N.; Chrysina, E. D.; Leon-idas, D. D.; Kostas, I. D.; Wendt, K. U.; Klabunde, T.; Defossa, E. Crystallographic studies on acyl ureas, a new class of glycogenphosphorylase inhibitors, as potential antidiabetic drugs. ProteinSci., 2005, 14(7), 1760-1771.
72. Defossa, E.; Klabunde, T.; Burger, H.-J.; Herling, A.; Von Roe-dern, E.; Peukert, S.; Enhsen, A.; Bauer, A.; Neises, B.; Wendt, K.U. Carboxamide-substituted phenylurea derivatives for the treat-ment of type II diabetes. PCT. Int. Appl.; WO 2002096864, 2002;p. 71.
73. Furukawa, S.; Tsurumi, Y.; Murakami, K.; Nakanishi, T.; Ohsumi, K.; Hashimoto, M.; Nishikawa, M.; Takase, S.; Nakayama, O.; Hino, M. FR258900, a novel glycogen phosphorylase inhibitor iso-lated from Fungus No. 138354. I. Taxonomy, fermentation, isola-tion and biological activities. J. Antibiot., 2005, 58(8), 497-502.
74. Furukawa, S.; Murakami, K.; Nakanishi, T.; Nakayama, O.; Hino, M. FR258900, a novel glycogen phosphorylase inhibitor isolatedfrom Fungus No. 138354. II. Anti-hyperglycemic effects in dia-betic animal models. J. Antibiot., 2005, 58(8), 503-506.
75. Tiraidis C.; Alexacou K-M.; Zographos S. E; Leonidas D. D; Gimisis T.; Oikonomakos N. G FR258900, a potential anti-hyperglycemic drug, binds at the allosteric site of glycogen phos-phorylase. Protein Sci., 2007, 16(8), 1773-82.
76. Sparks, S. M.; Banker, P.; Bickett, D. M.; Carter, H. L.; Clancy, D.C.; Dickerson, S. H.; Dwornik, K. A.; Garrido, D. M.; Golden, P.L.; Nolte, R. T.; Peat, A. J.; Sheckler, L. R.; Tavares, F. X.; Thom-son, S. A.; Wang, L.; Weiel, J. E. Anthranilimide-based glycogenphosphorylase inhibitors for the treatment of type 2 diabetes: 1.Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups. Bioorg. Med. Chem. Lett., 2009, 19(3), 976-980.
77. Sparks, S. M.; Banker, P.; Bickett, D. M.; Clancy, D. C.; Dicker-son, S. H.; Garrido, D. M.; Golden, P. L.; Peat, A. J.; Sheckler, L.R.; Tavares, F. X.; Thomson, S. A.; Weiel, J. E. Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type2 diabetes: 2. Optimization of serine and threonine ether aminoacid residues. Bioorg. Med. Chem. Lett., 2009, 19(3), 981-985.
78. Thomson, S. A.; Banker, P.; Bickett, D. M.; Boucheron, J. A.; Carter, H. L.; Clancy, D. C.; Cooper, J. P; Dickerson, S. H.; Gar-rido, D. M.; Nolte, R. T.; Peat, A. J.; Sheckler, L. R.; Sparks, S. M.; Tavares, F. X.; Thomson, S. A.; Wang, L.; Weiel, J. E. Anthra-nilimide-based glycogen phosphorylase inhibitors for the treatmentof Type 2 diabetes: Part 3. X-ray crystallographic characterization,core and urea optimization and in vivo efficacy. Bioorg. Med.Chem. Lett., 2009, 19(4), 1177-1182.
79. Evans, K. A.; Li, Y. H.; Coppo, F. T.; Graybill, T. L.; Cichy-Knight, M.; Patel, M.; Gale, J.; Li, H.; Thrall, S. H.; Tew, D.; Tava-res, F.; Thomson, S. A.; Weiel, J. E.; Boucheron, J. A.; Clancy, D.C.; Epperly, A. H.; Golden, P. L. Amino acid anthranilamide de-rivatives as a new class of glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(14), 4068-4071.
80. Anderka, O.; Loenze, P.; Klabunde, T.; Dreyer, M. K.; Defossa, E.; Wendt, K. U.; Schmoll, D. Thermodynamic Characterization of Al-losteric Glycogen Phosphorylase Inhibitors. Biochemistry, 2008,47(16), 4683-4691.
81. Wen, X.; Sun, H.; Liu, J.; Cheng, K.; Zhang, P.; Zhang, L.; Hao, J.; Zhang, L.; Ni, P.; Zographos, S. E.; Leonidas, D. D.; Alexacou, K.-M.; Gimisis, T.; Hayes, J. M.; Oikonomakos, N. G. Naturally Oc-curring Pentacyclic Triterpenes as Inhibitors of Glycogen Phos-phorylase: Synthesis, Structure-Activity Relationships, and X-rayCrystallographic Studies. J. Med. Chem., 2008, 51(12), 3540-3554.
82. Wen, X.; Xia, J.; Cheng, K.; Zhang, L.; Zhang, P.; Liu, J.; Zhang, L.; Ni, P.; Sun, H. Pentacyclic triterpenes. Part 5: Synthesis andSAR study of corosolic acid derivatives as inhibitors of glycogenphosphorylases. Bioorg. Med. Chem. Lett., 2007, 17(21), 5777-5782.
83. Wen, X.; Sun, H.; Liu, J.; Wu, G.; Zhang, L.; Wu, X.; Ni, P. Penta-cyclic triterpenes. Part 1: The first examples of naturally occurringpentacyclic triterpenes as a new class of inhibitors of glycogenphosphorylases. Bioorg. Med. Chem. Lett., 2005, 15(22), 4944-4948.
84. Wen, X.; Zhang, P.; Liu, J.; Zhang, L.; Wu, X.; Ni, P.; Sun, H. Pentacyclic triterpenes. Part 2: Synthesis and biological evaluationof maslinic acid derivatives as glycogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(3), 722-726.
85. Chen, J.; Liu, J.; Zhang, L.; Wu, G.; Hua, W.; Wu, X.; Sun, H. Pentacyclic triterpenes. Part 3: Synthesis and biological evaluationof oleanolic acid derivatives as novel inhibitors of glycogen phos-phorylase. Bioorg. Med. Chem. Lett., 2006, 16(11), 2915-2919.
86. Zhang, L.; Chen, J.; Gong, Y.; Liu, J.; Zhang, Lu.; Hua, W.; Sun, H. Synthesis and biological evaluation of asiatic acid derivatives asinhibitors of glycogen phosphorylases. Chem. Biodivers., 2009,6(6), 864-874.
87. Hao, J.; Zhang, X.; Zhang, P.; Liu, J.; Zhang, L.; Sun, H. Efficientaccess to isomeric 2,3-dihydroxy lupanes: first synthesis of alphi-tolic acid. Tetrahedron, 2009, 65(38), 7975-7984.
88. Zhu, P.; Bi, Y.; Xu, J.; Li, Z.; Liu, J.; Zhang, L.; Ye, W.; Wu, X. Terpenoids. III: Synthesis and biological evaluation of 23-hydroxybetulinic acid derivatives as novel inhibitors of glycogenphosphorylase. Bioorg. Med. Chem. Lett., 2009, 19(24), 6966-6969.
89. Cheng, K.; Zhang, P.; Liu, J.; Xie, J.; Sun, H. Practical Synthesis ofBredemolic Acid, a Natural Inhibitor of Glycogen Phosphorylase. J. Nat. Prod., 2008, 71(11), 1877-1880.
90. Chen, J.; Gong, Y.; Liu, J.; Hua, W.; Zhang, L.; Sun, H. Synthesisand biological evaluation of novel pyrazolo[4,3-b]oleanane deriva-tives as inhibitors of glycogen phosphorylase. Chem. Biodivers.,2008, 5(7), 1304-1312.
91. Luo, J-G.; Liu, J.; Kong, L-Y. New pentacyclic triterpenes fromGypsophila oldhamiana and their biological evaluation as glycogenphosphorylase inhibitors. Chem. Biodivers., 2008, 5(5), 751-757.
92. Zhang, P.; Hao, J.; Liu, J.; Lu, Q.; Sheng, H.; Zhang, L.; Sun, H. Synthesis of 3-Deoxypentacyclic Triterpene Derivatives as Inhibi-tors of Glycogen Phosphorylase. J. Nat. Prod., 2009, 72(8), 1414-1418.
93. Hoover, D. J.; Lefkowitz-Snow, S.; Burgess-Henry, J. L.; Martin, W. H.; Armento, S. J.; Stock, I. A.; McPherson, R. K.; Genereux, P. E.; Gibbs, E. M.; Treadway, J. L. Indole-2-carboxamide inhibi-tors of human liver glycogen phosphorylase. J. Med. Chem., 1998,41(16), 2934-2938.
94. Prathipati, P.; Pandey, G.; Saxena, A. K. CoMFA and DockingStudies on Glycogen Phosphorylase a Inhibitors as AntidiabeticAgents. J. Chem. Inform. Comput. Sci., 2005, 45(1), 136-145.
95. Onda, K.; Suzuki, T.; Shiraki, R.; Yonetoku, Y.; Ogiyama, T.; Maruyama, T.; Momose, K. Preparation of indole-2-carboxamidederivatives as glycogen phosphorylase inhibitors for treatment ofdiabetes. PCT. Int. Appl.; WO 2003091213, 2003.
96. Onda, K.; Shiraki, R.; Ogiyama, T.; Suzuki, T.; Maruyama, T.; Momose, K. Preparation of indolecarboxamides as glycogen phos-phorylase inhibitors. Jpn. Kokai Tokkyo Koho; JP 2004196702,2004.
97. Stocker, A.; Whittamore, P. R. O. Preparation of indolecarbox-amides that possess glycogen phosphorylase inhibitory activity. PCT. Int. Appl.; WO 2003074517, 2003.
98. Morley, A. D. Preparation of N-carbamoylmethylindolecarbox-amides as glycogen phosphorylase inhibitors. PCT. Int. Appl.; WO2003074485, 2003.
99. Whittamore, P. R. O.; Bennett, S. N. L.; Simpson, I. Preparation ofindolamide derivatives that possess glycogen phosphorylase inhibi-tory activity. PCT. Int. Appl.; WO 2003074484, 2003.
100. Nakamura, T.; Takagi, M.; Ueda, N. Preparation of indole deriva-tives as inhibitors of human liver glycogen phosphorylase a. PCT.Int. Appl.; WO 2003037864, 2003.
101. Birch, A. M.; Morley, A. D. Preparation of N-heterocyclyl indole-2-carboxamides as glycogen phosphorylase inhibitors. PCT. Int.Appl.; WO 2003074513, 2003.
102. Bennett, S. N. L.; Simpson, I.: Preparation of indole-2-carboxamidederivatives as glycogen phosphorylase inhibitors. PCT. Int. Appl.;WO 2005020985, 2005.
103. Bennett, S. N. L.; Simpson, I.; Whittamore, P. R. O. Preparation ofindole-2-carboxamide derivatives as glycogen phosphorylase in-hibitors. PCT. Int. Appl.; WO 2005019172, 2005.
104. Birch, A. M.; Bennett, S. N. L.; Godfrey, L.; Simpson, I.; Whitta-more, P. R. O. Preparation of indole-2-carboxamide derivatives asglycogen phosphorylase inhibitors. PCT. Int. Appl.; WO2005013975, 2005.
105. Sher, P. M.; Wu, G.; Meng, W.; Nirschl, A. A.; Washburn, W. N.; Stouch, T. Preparation of chloroindolecarboxamides as glycogenphosphorylase inhibitors. U.S. Pat. Appl. Publ.; US 2006111413,2006.
106. Wu, G.; Sher, P. M. Preparation of 2-amino-1-functionalizedtetralin derivatives and related glycogen phosphorylase inhibitors. PCT. Int. Appl.; WO 2006053274, 2006.
107. Bradley, S. E.; Jeevaratnam, R. P.; Krulle, T. M.; Procter, M. J.; Rowley, R. J.; Thomas, G. H.; Valdes, A. Preparation of pyr-rolopyridine-2-carboxylic acid hydrazides as glycogen phosphory-lase inhibitors. PCT. Int. Appl.; WO 2005085245, 2005.
108. Wright, S. W.; Rath, V. L.; Genereux, P. E.; Hageman, D. L.; Levy, C. B.; McClure, L. D.; McCoid, S. C.; McPherson, R. K.; Schelhorn, T. M.; Wilder, D. E.; Zavadoski, W. J.; Gibbs, E. M.; Treadway, J. L. 5-Chloroindoloyl glycine amide inhibitors of gly-cogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystal-lographic characterization. Bioorg. Med. Chem. Lett., 2005, 15(2),459-465.
109. Harwood, H. J., Jr.; Petras, S. F.; Hoover, D. J.; Mankowski, D. C.; Soliman, V. F.; Sugarman, E. D.; Hulin, B.; Kwon, Y.; Gibbs, E.M.; Mayne, J. T.; Treadway, J. L. Dual-action hypoglycemic andhypocholesterolemic agents that inhibit glycogen phosphorylaseand lanosterol demethylase. J. Lipid Res., 2005, 46(3), 547-563.
110. Onda, K.; Shiraki, R.; Yonetoku, Y.; Momose, K.; Katayama, N.; Orita, M.; Yamaguchi, T.; Ohta, M.; Tsukamoto, S-I. Synthesis andpharmacological evaluation of bis-3-(3,4-di chlorophenyl)acryl-amide derivatives as glycogen phosphorylase inhibitors. Bioorg.Med. Chem., 2008, 16(18), 8627-8634.
111. Birch, A. M.; Kenny, P. W.; Oikonomakos, N. G.; Otterbein, L.; Schofield, P. Whittamore P. R. O.; Whalley D. P. Development ofpotent, orally active 1-substituted-3,4-dihydro-2-quinolone glyco-gen phosphorylase inhibitors. Bioorg. Med. Chem. Lett., 2007,17(2), 394-399.
112. Defossa, E.; Kadereit, D.; Schoenafinger, K.; Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U.; Von Roedern, E.; Enhsen, A. Preparation of 3-(benzoylureido)benzoic acids as antidiabetics. PCT. Int. Appl.; WO 2003084923, 2003.
113. Defossa, E.; Kadereit, D.; Schoenafinger, K.; Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U.; Von Roedern, E.; Enhsen, A.; Ri-eke-Zapp, J.: Preparation of 4-(benzoylureido)benzoic acids as an-tidiabetics. PCT. Int. Appl.; WO 2003084922, 2003.
114. Defossa, E.; Kadereit, D.; Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U.; Von Roedern, E.; Schoenafinger, K.; Enhsen, A. Preparation of benzoylureas for the treatment of diabetes mellitus. Ger. Offen.; DE 10246434, 2004.
115. Verma, S. S.; Mishra, R. C.; Tamarakar, A. K.; Tripathi, B. K.; Srivastava, A. K.; Tripathi, R. P. Reductive Amination of GlycosylAldoses: Synthesis of N-Glycosylated -Glycosyl Amino Alcoholsand their Enzyme Inhibitory Effect. J. Carbohydr. Chem., 2004,23(8-9), 493-511.
116. Bradley, S. E.; Jeevaratnam, R. P.; Krulle, T. M.; Procter, M. J.; Rowley, R. J.; Thomas, G. H.; Valdes, A. Indole-2-carboxylic acidhydrazides. PCT. Int. Appl.; WO 2005085194, 2005.
117. Gammill, R. B. Preparation of substituted 1H-indole-2-carboxamides and 6H-thieno[2,3-b]pyrrole-5-carboxamides as an-tidiabetic agents. PCT. Int. Appl.; WO 2003072570, 2003.
118. Birch, A. M.; Kenny, P. W.; Simpson, I.; Whittamore, P. R.O.Matched molecular pair analysis of activity and properties of gly-cogen phosphorylase inhibitors. Bioorg. Med. Chem. Lett., 2009,19(3), 850-853.
119. Whittamore, P. R. O.; Addie, M. S.; Bennett, S. N. L.; Birch, A.M.; Butters, M.; Godfrey, L.; Kenny, P. W.; Morley, A. D.; Murray, P. M.; Oikonomakos, N. G.; Otterbein, L. R.; Pannifer, A.D.; Parker, J. S.; Readman, K.; Siedlecki, P. S.; Schofield, P.; Stocker, A.; Taylor, M. J.; Townsend, L. A.; Whalley, D. P.; Whitehouse, J. Novel thienopyrrole glycogen phosphorylase inhibi-tors: synthesis, in vitro SAR and crystallographic studies. Bioorg.Med. Chem. Lett., 2006, 16(21), 5567-5571.
120. Freeman, S.; Bartlett, J. B.; Convey, G.; Hardern, I.; Teague, J. L.; Loxham, S. J. G.; Allen, J. M.; Poucher, S. M.; Charles, A. D. Sen-sitivity of glycogen phosphorylase isoforms to indole site inhibitorsis markedly dependent on the activation state of the enzyme. Br. J.Pharmacol., 2006, 149(6), 775-85.
121. Bartlett, J. B.; Freeman, S.; Kenny, P.; Morley, A.; Whittamore, P. Preparation of bicyclic pyrrolyl amides as glycogen phosphorylaseinhibitors. PCT. Int. Appl.; WO 2002020530, 2002.
122. Birch, A. M.; Bennett, S. N. L.; Campbell, A. D.; Simpson, I.; Whittamore, P. R. O.; Whalley, D. P.; Godfrey, L. Preparation ofthienopyrrole amide derivatives as glycogen phosphorylase inhibi-tors. PCT. Int. Appl.; WO 2005013981, 2005.
123. Bussolotti, D. L.; Gammill, R. B.; Polivkova, J. Preparation ofsubstituted 1H-indole-2-carboxamides and 6H-thieno[2,3-b]pyrrole-5-carboxamides as antidiabetic agents. PCT. Int. Appl.;WO 2004041780, 2004.
124. Bussolotti, D. L.; Gammill, R. B. A preparation of indolecarbox-amide and thieno[2,3-b]pyrrolecarboxamide derivatives, useful asantidiabetic agents. U.S. Pat. Appl. Publ.; US 2004220229, 2004.
125. Bennett, S. N. L.; Simpson, I. Preparation of thienopyrrole carbox-amides as glycogen phosphorylase inhibitors. PCT. Int. Appl.; WO2005020986, 2005.
126. Birch, A. M.; Simpson, I.; Stocker, A.; Whittamore, P. R. O. Prepa-ration of thieno[3,2-b]pyrrole amide derivatives as glycogen phos-phorylase inhibitors. PCT. Int. Appl.; WO 2005020987, 2005.
127. Bennett, S. N. L.; Simpson, I.; Whittamore, P. R. O. Preparation ofthieno[2,3-b]pyrrole-5-carboxamide derivatives as glycogen phos-phorylase inhibitors. PCT. Int. Appl.; WO 2005018637, 2005.
128. Sher, P. M.; Ellsworth, B. A. Triglyceride and triglyceride-likeprodrugs of glycogen phosphorylase inhibiting compounds. U.S.Pat. Appl. Publ.; US 2004142938, 2004.
129. Sher, P.; Wu, G.; Stouch, T.; Ellsworth, B. Lactam glycogen phos-phorylase inhibitors and their use in disease treatment. U.S. Pat.Appl. Publ.; US 2004002495, 2004.
130. Sher, P. M.; Nirschl, A. A.; Meng, W.; Washburn, W. N. Prepara-tion of heteroaroylaminotetralins and related compounds as glyco-gen phosphorylase inhibitors. U.S. Pat. Appl. Publ.; US2006111338, 2006.
131. Onda, K.; Shiraki, R.; Ogiyama, T.; Yokoyama, K.; Momose, K.; Katayama, N.; Orita, M.; Yamaguchi, T.; Furutani, M.; Hamada, N.; Takeuchi, M.; Okada, M.; Ohta, M.; Tsukamoto, S-I. Design,synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phos-phorylase inhibitors. Bioorg. Med. Chem., 2008, 16(23), 10001-10012.
132. Onda, K.; Suzuki, T.; Shiraki, R.; Yonetoku, Y.; Negoro, K.; Mo-mose, K.; Katayama, N.; Orita, M.; Yamaguchi, T.; Ohta, M.; Tsu-kamoto, S-I. Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogenphosphorylase a. Bioorg. Med. Chem., 2008, 16(10), 5452-5464.
133. Chen, L.; Li, H.; Liu, J.; Zhang, L.; Liu, H.; Jiang, H. Discoveringbenzamide derivatives as glycogen phosphorylase inhibitors andtheir binding site at the enzyme. Bioorg. Med. Chem., 2007, 15(21),6763-6774.
134. Schoenafinger, K.; Kadereit, D.; Defossa, E.; Herling, A.; Klabun-de, T.: Preparation of benzoylureidopyridylpiperidines for thetreatment of type 2 diabetes. PCT. Int. Appl.; WO 2004078743,2004.
135. Schoenafinger, K.; Defossa, E.; Von Roedern, E.; Kadereit, D.; Herling, A.; Burger, H.-j.; Klabunde, T.; Wendt, K.-U. Preparationof 3-(benzoylureido)thiophenes as glycogen phosphorylase inhibi-tors. PCT. Int. Appl.; WO 2004072060, 2004.
136. Defossa, E.; Kadereit, D.; Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U.; Von Roedern, E.; Schoenafinger, K.; Enhsen, A. Preparation of 3-(benzoylureido)benzoic acids as antidiabetics. PCT. Int. Appl.; WO 2004065356, 2004.
137. Schoenafinger, K.; Defossa, E.; Kadereit, D.; Von Roedern, E.; Klabunde, T.; Burger, H.-J.; Herling, A.; Wendt, K.-U. Preparationof heterocyclylbenzoylureas for treating type 2 diabetes. PCT. Int.Appl.; WO 2004007455, 2004.
138. Beavers, M. P.; Dudash, J.; Zhang, Y. Preparation of heteroaroy-laminotetralins and related compounds as glycogen phosphorylaseinhibitors: U.S. Pat. Appl. Publ.; US 2005148586, 2005.
139. Dudash, J., Jr.; Zhang, Y.; Moore John, B.; Look, R.; Liang, Y.; Beavers Mary, P.; Conway Bruce, R.; Rybczynski Philip, J. De-marest Keith, T. Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors. Bioorg. Med.Chem. Lett., 2005, 15(21), 4790-4793.
140. Defossa, E.; Kadereit, D.; Klabunde, T.; Schmoll, D.; Herling, A.; Wendt, K.-U.; Ruf, S. Preparation of 7-amino-4-quinolone-3-carboxylic acids and related compounds for the treatment of type 2diabetes. PCT. Int. Appl.; WO 2005073231, 2005.
141. Defossa, E.; Kadereit, D.; Ruf, S.; Klabunde, T.; Schmoll, D.; Herling, A.; Wendt, K.-U. Preparation of 7-amino-4-quinolone-3-carboxylic acids and related compounds for the treatment of type 2diabetes: PCT. Int. Appl.; WO 2005073230, 2005.
142. Defossa, E.; Kadereit, D.; Ruf, S.; Klabunde, T.; Schmoll, D.; Herling, A.; Wendt, K.-U. Preparation of 7-phenylamino-4-quinolone-3-carboxylic acids and related compounds for the treat-ment of type 2 diabetes. PCT. Int. Appl.; WO 2005073229, 2005.
143. Whittamore, P. R. O.; Bennett, S. N. L.; Simpson, I. Preparation ofheterocyclic amide derivatives having glycogen phosphorylase in-hibitory activity. PCT. Int. Appl.; 2003074531, 2003.
144. Birch, A. M.; Morley, A. D.; Stocker, A.; Whittamore, P. R. O. Preparation of heterocyclic amides as inhibitors of glycogen phos-phorylase. PCT. Int. Appl.; WO 2003074532, 2003.
145. Bussolotti, D. L.; Gammill, R. B. N-(Pyridin-2-yl)-substitutedbicyclic heterocyclic carboxamide derivatives as antidiabeticagents, and their preparation, pharmaceutical compositions, and methods of use as inhibitors of glycogen phosphorylase. PCT. Int.Appl.; WO 2004092158, 2004.
146. Li, Y. H.; Coppo, F. T.; Evans, K. A.; Graybill, T. L.; Patel, M.; Gale J.; Li H.; Tavares F.; Thomson S. A. Synthesis and structure-activity relationships of 3-phenyl-2-propenamides as inhibitors ofglycogen phosphorylase a. Bioorg. Med. Chem. Lett., 2006, 16(22),5892-5896.
147. Daisy, J. Preparation of fused pyrrolylcarboxamides as glycogenphosphorylase inhibitors. Eur. Pat. Appl.; EP 1391460, 2004.
148. Joe, D. Preparation of bicyclic pyrrolylcarboxamides as glycogenphosphorylase inhibitors. Eur. Pat. Appl.; EP 1088824, 2001.
149. Bradley, S. E.; Krulle, T. M.; Murray, P. J.; Procter, M. J.; Rowley, R. J.; Sambrook Smith, C. P.; Thomas, G. H. Preparation of pyr-rolopyridine-2-carboxylic acid amide as inhibitors of glycogenphosphorylase. PCT. Int. Appl.; WO 2004104001, 2004.
150. Karis, N. D.; Loughlin, W. A.; Jenkins, I. D.; Healy, P.C. Glycogenphosphorylase Inhibitory effects of 2-oxo-1,2-dihydropyridin-3-ylamide derivatives. Bioorg. Med. Chem., 2009, 17(13), 4724-4733.
151. Juhasz L.; Docsa T.; Brunyaszki A.; Gergely P.; Antus S. Synthesisand glycogen phosphorylase inhibitor activity of 2,3-dihydrobenzo[1,4]dioxin derivatives. Bioorg. Med. Chem., 2007,15(13), 4048-56.
152. Jakobs, S.; Fridrich, D.; Hofem, S.; Pahlke, G.; Eisenbrand, G.Natural flavonoids are potent inhibitors of glycogen phosphorylase.Mol. Nutr. Food Res., 2006, 50(1), 52-57.
153. Kato, A.; Nasu, N.; Takebayashi, K.; Adachi, I.; Minami, Y.; Sanae, F.; Asano, N.; Watson, A. A.; Nash, R. J. Structure-ActivityRelationships of Flavonoids as Potential Inhibitors of GlycogenPhosphorylase. J. Agric. Food Chem., 2008, 56(12), 4469-4473.
154. Li, J.; Lu, Y.; Su, X.; Li, F.; She, Z.; He, X.; Lin, Y. A norses-quiterpene lactone and a benzoic acid derivative from the leaves ofCyclocarya paliurus and their glucosidase and glycogen phosphory-lase inhibiting activities. Planta Med., 2008, 74(3), 287-289.
155. Loughlin, W. A.; Pierens, G. K.; Petersson, M. J.; Henderson, L.C.; Healy, P. C. Evaluation of novel hyphodermin derivatives asGlycogen Phosphorylase a inhibitors. Bioorg. Med. Chem., 2008,16(11), 6172-6178.
156. Motoshima, K.; Ishikawa, M.; Sugita, K.; Hashimoto, Y. Glycogenphosphorylase a inhibitors with a phenethylphenylphthalimideskeleton derived from thalidomide-related -glucosidase inhibitorsand liver X receptor antagonists. Biol. Pharm. Bull., 2009, 32(9),1618-1620.
157. Singh, F. V.; Parihar, A.; Chaurasia, S.; Singh, A. B.; Singh, S.P.; Tamrakar, A. K.; Srivastava, A. K.; Goel, A. 5,6-Diarylanthranilo-1,3-dinitriles as a new class of antihyperglycemic agents. Bioorg.Med. Chem. Lett., 2009, 19(8), 2158-2161.
158. 2+ release in skeletal muscle. Biochem. J., 2003, 371, 81-88.
159. Munro, S.; Cuthbertson, D. J. R.; Cunningham, J.; Sales, M.; Cohen, P. T. W. Human skeletal muscle expresses a glycogen-targeting subunit of PP1 that is identical to the insulin-sensitiveglycogen-targeting subunit GL of liver. Diabetes, 2002, 51(3), 591-598.
160. Armstrong, C. G.; Doherty, M. J.; Cohen, P. T. W. Identification ofthe separate domains in the hepatic glycogen-targeting subunit ofprotein phosphatase 1 that interact with phosphorylase a, glycogenand protein phosphatase 1. Biochem. J., 1998, 336, 699-704.
161. Doherty, M. J.; Moorhead, G.; Morrice, N.; Cohen, P.; Cohen, P. T.W. Amino acid sequence and expression of the hepatic glycogen-binding (GL)-subunit of protein phosphatase-1. FEBS Lett., 1995,375(2), 294-298.
162. Kelsall, I. R.; Rosenzweig, D.; Cohen, P. T. W. Disruption of theallosteric phosphorylase a regulation of the hepatic glycogen-targeted protein phosphatase 1 improves glucose tolerance in vivo. Cell. Signal., 2009, 21(7), 1123-1134.
163. Kelsall, I. R.; Munro, S.; Hallyburton, I.; Treadway, J. L.; Cohen, P.T.W. The hepatic PP1 glycogen-targeting subunit interactionwith phosphorylase a can be blocked by C-terminal tyrosine dele-tion or an indole drug. FEBS Lett., 2007, 581(24), 4749-4753.
164. Zibrova, D.; Grempler, R.; Streicher, R.; Kauschke, S. G. Inhibitionof the interaction between protein phosphatase 1 glycogen-targeting subunit and glycogen phosphorylase increases glycogensynthesis in primary rat hepatocytes. Biochem. J., 2008, 412(2),359-366.
165. Pautsch, A.; Stadler, N.; Wissdorf, O.; Langkopf, E.; Moreth, W.; Streicher, R. Molecular Recognition of the Protein Phosphatase 1Glycogen Targeting Subunit by Glycogen Phosphorylase. J. Biol.Chem., 2008, 283, 8913-8918.
166. Schweiker, S. S.; Loughlin, W. A.; Brown, C. L.; Pierens, G. K. Synthesis of new modified truncated peptides and inhibition of gly-cogen phosphorylase. J. Pept. Sci., 2009, 15(6), 442-450.
167. Langkopf, E.; Himmelsbach, F.; Mack, J.; Pautsch, A.; Schoelch, C.; Schuler-Metz, A.; Streicher, R.; Wagner, H. Preparation of newsubstituted arylsulphonylglycines as inhibitors of the interactionbetween glycogen phosphorylase and GL subunit of glycogen -associated protein phosphatase 1 and their pharmaceutical compo-sitions useful for treating diabetes. PCT. Int. Appl.; WO2009127723, 2009.
168. Wagner, H.; Langkopf, E.; Eckhardt, M.; Streicher, R.; Schoelch, C.; Schuler-Metz, A.; Pautsch, A. Substituted N-heterocyclic aryl-sulfonylaminomethylphosphonic acid derivatives as medicamentsfor treatment of Type I and II Diabetes mellitus and process fortheir preparation. PCT. Int. Appl.; WO 2009016119, 2009.
169. Wagner, H.; Langkopf, E.; Eckhardt, M.; Streicher, R.; Schoelch, C.; Schuler-Metz, A.; Pautsch, A. Substituted N-heterocyclic aryl-sulfonylaminomethylphosphonic acid derivatives as medicamentsfor treatment of Type I and II Diabetes mellitus and process fortheir preparation. Ger. Offen.; DE 102007035334 Ger. Offen. 2009.